Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Learn Which Crypto Assets Are Considered Low Risk and how to compare safety factors. This intro helps you screen assets with prudent criteria.
27,883 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A cold email from a Dallas founder led Mark Cuban to back a nascent space company with $500,000. Today, Relativity Sp...
Super Micro Computer and Dell Technologies rebounded after a sharp Monday drop tied to a Taiwan probe, with AI server...
Prediction markets promise quick wins, but long-term wealth tends to come from owning durable businesses. This guide ...
Navigator (NVGS) 2025 earnings paint a picture of a niche LNG carrier operator balancing utilization, rates and lever...
Two popular ETFs vie for attention in growth-heavy markets. This guide breaks down what each fund owns, how they beha...
Even as oil prices swing widely, four energy dividend giants have kept their payouts steady and growing. This piece l...
As Johnson & Johnson prepares July earnings, investors weigh the real case buying johnson thesis driven by durable in...
Markets are betting that rates will edge lower this year, nudging investors toward income-focused and rate-sensitive ...
A widening gap between data-center demand and supply is boosting heavy equipment and power-management stocks. Discove...
Analysts say cheap power, vast manufacturing, and a surge in open-source AI development could make China the big winn...
A New Jersey family faces nearly $300,000 in student debt against a paid-off $450,000 home and a $107k gross income, ...